natgillin/translations-raw huggingface dataset:
Kvalme, åndenød, uregelmæssig hjerterytme (puls), uklar urin, træthed og/eller ubehag forbundet med abnorme resultater af laboratorieprøver (f.eks. højt indhold af kalium, urinsyre og calcium i blodet og lavt indhold af fosfor i blodet).
Nausea, shortness of breath, irregular heartbeat, clouding of urine, tiredness and/or joint discomfort associated with abnormal laboratory test results (eg. high potassium, uric acid and calcium levels and low phosphorous levels in the blood).
Kvalme, åndenød, uregelmæssig hjerterytme (puls), uklar urin, træthed og/eller ubehag forbundet med abnorme resultater af laboratorieprøver (f.eks. højt indhold af kalium-, urinsyre- og calcium i blodet og lavt indhold af fosfor i blodet).
Nausea, shortness of breath, irregular heartbeat, clouding of urine, tiredness and/or joint discomfort associated with abnormal laboratory test results (e.g. high potassium, uric acid and calcium levels and low phosphorus levels in the blood).
Kvalme, åndenød, uregelmæssig hjerterytme (puls), uklar urin, træthed og/eller ubehag forbundet med abnorme resultater af laboratorieprøver (f.eks. højt kalium-, urinsyre- og calcium og lavt fosforniveau i blodet).
Nausea, shortness of breath, irregular heartbeat, clouding of urine, tiredness and/or joint discomfort associated with abnormal laboratory test results (eg. high potassium, uric acid and calcium levels and low phosphorous levels in the blood).
Kvalme, åndenød, uregelmæssig hjerterytme (puls), uklar urin, træthed og/eller ubehag forbundet med abnorme resultater af laboratorieprøver (f.eks. højt kalium-, urinsyre- og calciumniveau og lavt fosforniveau i blodet).
Nausea, shortness of breath, irregular heartbeat, clouding of urine, tiredness and/or joint discomfort associated with abnormal laboratory test results (eg. high potassium, uric acid and calcium levels and low phosphorus levels in the blood).
Kvalme, åndenød, uregelmæssig hjerterytme (puls), uklar urin, træthed og/eller ubehag forbundet med abnorme resultater af laboratorieprøver (f.eks. højt kalium-, urinsyre- og fosforniveau og lavt calcium i blodet ).
Nausea, shortness of breath, irregular heartbeat, clouding of urine, tiredness and/or joint discomfort associated with abnormal laboratory test results (eg. high potassium, uric acid and calcium levels and low phosphorous levels in the blood).
Kvalme, åndenød, uregelmæssig hjerterytme (puls), uklar urin, træthed og/eller ubehag forbundet med abnorme resultater af laboratorieprøver (f.eks. højt kalium-, urinsyre- og fosforniveau og lavt calcium i blodet).
Nausea, shortness of breath, irregular heartbeat, clouding of urine, tiredness and/or joint discomfort associated with abnormal laboratory test results (eg. high potassium, uric acid and calcium levels and low phosphorous levels in the blood).
kvalme, åndenød, uregelmæssig hjerterytme (puls), uklar urin, træthed og/eller ømme led forbundet med abnorme blodprøveresultater (f.eks. højt kalium-, urinsyre- og phosphatniveau og lavt calciumniveau)
nausea, shortness of breath, irregular heartbeat, clouding of urine, tiredness and/or joint discomfort associated with abnormal results of blood tests (such as high levels of potassium, uric acid and phosphorous and low levels of calcium)
Kvalme.
Feeling sick (nausea)
Kvalme.
Nausea (feeling sick)
kvalme/opkastning
feeling sick/being sick
kvalme/opkastning
nausea/vomiting
Kvalme/opkastning, mavesmerte, diarré, stomatitis, dyspepsi
Nausea/vomiting, abdominal pain, diarrhoea, stomatitis, dyspepsia
Kvalme1
Bone pain
kvalme1,3, forhøjet pankreatisk amylase1
nausea1, 3, increased pancreatic amalyse1
Kvalme2
Nausea2
Kvalme2 Opkastning1
Nausea2 Vomiting1 Diarrhoea1
Kvalme: hvis du mister appetitten, og hvis du spiser meget mindre hver dag end du plejer.
Nausea: if you lose your appetite, and the amount of food you eat each day is much less than usual.
Kvalme: hvis du mister appetitten, og hvis du spiser meget mindre hver dag, end du plejer.
Nausea: if you lose your appetite, and the amount of food you eat each day is much less than usual.
Kvalme; diarré; opkastning; konstipation; stomatitis; dyspepsi; mavesmerter
Abdominal pain upper; Dry mouth
Kvalme; diarré; opkastning; konstipation; stomatitis; dyspepsi; mavesmerter
Nausea; Diarrhoea; Vomiting; Constipation; Stomatitis; Dyspepsia; Abdominal pain
Kvalme; Diarré; Opkastning; Obstipation; Stomatitis; Dyspepsi; Mavesmerter
Nausea; Diarrhoea; Vomiting; Constipation; Stomatitis; Dyspepsia; Abdominal pain
kvalme; opkastning; brystsmerter.
feeling sick; vomiting; chest pain.
Kvalme; opkastning; diarré; dyspepsi
nausea, vomiting, diarrhoea, dyspepsia
Kvalme†
Nausea
Kvantificerbar PD-L1-tumorekspression blev målt hos 79% af patienterne i nivolumab-gruppen og hos 77% af patienterne i docetaxel-gruppen.
Quantifiable tumour PD-L1 expression was measured in 79% of patients in the OPDIVO group and 77% of patients in the docetaxel group.
Kvantificering af anti-Xa’s og anti-IIa’s farmakokinetiske aktivitet blev valideret vha. den amidolytiske metode med specifikke substrater og en enoxaparinstandard kalibreret mod den internationale standard (NIBSC) for lavmolekylære hepariner (LMH).
Quantitation of pharmacokinetic activity of anti-Xa and anti-IIa was validated by using the amidolytic method with specific substrates and enoxaparin standard calibrated against the international standard (NIBSC) for low molecular weight heparins (LMWHs).
kvartal 2020 og 4.
2018, Q4 2020, and
kvartal 2022).
Q4 2022).
kvartal 2024
By Q3 2024
Kvartalsmæssigt herefter.
Quarterly thereafter.
Kvindelig patient i den fertile alder
Female patient of childbearing potential
Kvindelig patient, som ikke er i den fertile alder
Female patient of non-childbearing potential
Kvindelig population ≥ 27 år gammel
Woman population ≥ 27 years of age
Kvindelige og mandlige medarbejdere, som prøver at få børn og kvindelige medarbejdere, som er gravide, bør undtages fra arbejde med substansen;
male and female staff who are trying to conceive and female staff who are pregnant should be excluded from working with the substance;
Kvindelige patienter der tager pioglitazon har almindeligvis rapporteret om knoglebrud (op til 1 ud af 10 personer).
Broken bones have been reported commonly (up to 1 in 10 people) in women patients taking pioglitazone.
Kvindelige patienter havde en 15 % højere plasmaeksponering (AUCτ,ss, korrigeret for legemsvægt) end mandlige patienter.
Female patients had a 15% higher plasma exposure (AUCτ,ss, body weight corrected) than male patients.
Kvindelige patienter i den fertile alder skal anvende effektiv prævention, og gravide kvinder bør ikke få Eylea.
Female patients of childbearing potential have to use effective contraception and pregnant women should not use Eylea
Kvindelige patienter i den fødedygtige alder og deres mandlige partnere
Female patients of childbearing age and their male partners
Kvindelige patienter og deres partnere skal derfor bruge prævention af barrieretypen, såsom kondom.
Women and their partners should therefore also use a barrier method of contraception such as condoms.
Kvindelige patienter og patienter med høje CD4-celletal (> 250 celler/mm3 for kvinder og > 400 celler/mm3 for mænd) ved initiering af nevirapin-behandling, og som har et detekterbart plasmaniveau af hiv-1-rna – dvs. ≥ 50 kopier/ml - har en højere risiko for leverpåvirkninger.
Female gender and higher CD4 counts (>250/mm3 in adult females and >400/mm3 in adult males) at the initiation of nevirapine therapy are associated with a greater risk of hepatic adverse reactions if the patient has detectable plasma HIV-1 RNA - i.e. a concentration ≥ 50 copies/ml - at the initiation of nevirapine.
Kvindelige patienter skal have en rutine-graviditetstest udført hver måned under behandling og i fire måneder derefter.
Female patients must have a routine pregnancy test performed monthly during treatment and for four months thereafter.
Kvindelige patienter, lav legemsvægt og underliggende nedsat nyrefunktion
Female gender, lower body weight, and underlying renal impairment
Kvindelige patienters mulighed for at blive gravid.
Determination of child-bearing potential in female patients.
Kvinden bekræfter, at hun forstår risikoen og de nødvendige sikkerhedsforanstaltninger, som er forbundet med brugen af lenalidomid.
She acknowledges that she understands the hazards and necessary precautions associated with the use of lenalidomide.
Kvinden bekræfter, at hun forstår risikoen og de nødvendige sikkerhedsforanstaltninger, som er forbundet med brugen af pomalidomid.
She acknowledges that she understands the hazards and necessary precautions associated with the use of pomalidomide.
Kvinden er oplyst om og har indsigt i den forventede teratogene risiko for det ufødte barn
She understands the expected teratogenic risk to the unborn child
Kvinden forstår nødvendigheden af at påbegynde behandlingen, så snart lenalidomid er blevet ordineret efter en negativ graviditetstest
She understands the need to commence the treatment as soon as lenalidomide is dispensed following a negative pregnancy test
Kvinden forstår nødvendigheden af at påbegynde behandlingen, så snart pomalidomid er blevet ordineret efter en negativ graviditetstest
She understands the need to commence the treatment as soon as pomalidomide is dispensed following a negative pregnancy test
Kvinden forstår nødvendigheden af en effektiv, uafbrudt prævention, 4 uger før behandlingen indledes, under hele behandlingsforløbet og 4 uger efter behandlingens afslutning
She understands the need for effective contraception, without interruption, 4 weeks before starting treatment, throughout the entire duration of treatment, and 4 weeks after the end of treatment
Kvinden forstår nødvendigheden af en sikker, uafbrudt kontraception 4 uger før behandlingen indledes, under hele behandlingsforløbet og i 4 uger efter behandlingens afslutning
She understands the need for effective contraception, without interruption, 4 weeks before starting treatment, throughout the entire duration of treatment, and 4 weeks after the end of treatment
Kvinden forstår nødvendigheden af og accepterer at få foretaget en graviditetstest hver 4. uge undtagen ved bekræftet æggeleder-sterilisation
She understands the need and accepts to undergo pregnancy testing every 4 weeks except in case of confirmed tubal sterilisation
Kvinden forstår nødvendigheden af og accepterer at få foretaget graviditetstest hver 4. uge, undtagen ved bekræftet æggeleder-sterilisation
She understands the need and accepts to undergo pregnancy testing every 4 weeks except in case of confirmed tubal sterilisation
Kvinden har fået information om og forstår de potentielle følger af graviditet og nødvendigheden af omgående at søge læge, hvis der er risiko for graviditet
She is informed and understands the potential consequences of pregnancy and the need to rapidly consult if there is a risk of pregnancy
Kvinden kan også tilrådes at ophøre med at tage de aktive tabletter fra det aktuelle blisterkort.
The woman may also be advised to discontinue active tablet-taking from the current blister pack.
Kvinden kan skifte når som helst fra tabletter kun med progesteron (minipiller) (fra et implantat på dagen for dettes fjernelse, fra en injektionsvæske, når den næste injektion skulle gives), men der bør samtidig anvendes et ikke-hormonalt præventionsmiddel i de første 7 dage.
The woman may switch any day from the progestogen-only pill (from an implant on the day of its removal, from an injectable when the next injection would be due), but a back-up barrier method of birth control must be used during the first 7 days.
Kvinden skal påsætte det første depotplaster i den nye cyklus, så snart hun husker det.
The user should apply the first transdermal patch of the new cycle as soon as remembered.
Kvinden skal være i stand til at benytte effektive præventionsmetoder
She should be capable of complying with effective contraceptive measures
Kvinden skal være i stand til at overholde effektive præventionsmetoder
She should be capable of complying with effective contraceptive measures
Kvinden vil muligvis ikke være beskyttet mod graviditet.
The user may not be protected from pregnancy.
Kvinder
Female gender
Kvinder bør anvende effektiv prævention under behandling med Ilaris og i op til 3 måneder efter den sidste dosis.
Women should use effective contraceptives during treatment with Ilaris and for up to 3 months after the last dose.
Kvinder bør desuden undgå at blive gravide i et tidsrum af en måned efter at have ophørt med behandlingen.
Women should also not become pregnant for one month after stopping treatment.
Kvinder bør ikke amme under behandling med ORENCIA samt i 14 uger efter sidste abatacept-dosis.
Women should not breastfeed while treated with ORENCIA and for up to 14 weeks after the last dose of abatacept treatment.
Kvinder bør ikke blive gravide under behandling med Efavirenz Teva og i 12 uger efter ophørt behandling.
Women should not get pregnant during treatment with Efavirenz Teva and for 12 weeks thereafter.
Kvinder bør ikke blive gravide under behandling med Stocrin og i 12 uger efter ophørt behandling.
Women should not get pregnant during treatment with Stocrin and for 12 weeks thereafter.
Kvinder bør ikke blive gravide under behandling med SUSTIVA og i 12 uger efter ophørt behandling.
Women should not get pregnant during treatment with SUSTIVA, and for 12 weeks thereafter.
Kvinder bør undgå at blive gravide, mens de tager Gilenya og i to måneder efter behandlingens ophør.
Women should avoid becoming pregnant while taking Gilenya and for two months after treatment has stopped.
Kvinder der er i stand til at blive gravide, skal bruge sikker prævention under behandlingen og op til 5 måneder efter behandlingen.
Women who are able to get pregnant should use effective contraception during treatment and up to 5 months after treatment.
Kvinder der kan blive gravide bør bruge effektiv prævention.
Women who might become pregnant are advised to use effective contraception during treatment.
Kvinder har 3 gange større risiko end mænd for symptomatiske, ofte udslætassocierede leverpåvirkninger (5,8 % versus 2,2 %), og behandlingsnaive patienter af begge køn med detekterbart hiv-1-RNA i plasma og med et højere CD4-celletal ved behandlingsstart med nevirapin, har en større risiko for symptomatisk leverpåvirkning under nevirapin-behandling.
Women have a three fold higher risk than men for symptomatic, often rash-associated, hepatic events (5.8 % versus 2.2 %), and treatment-naïve patients of either gender with detectable HIV-1 RNA in plasma with higher CD4 counts at initiation of nevirapine therapy are at higher risk for symptomatic hepatic events with nevirapine.
Kvinder i den fertile alder
Women of childbearing potential/Contraception in males and females
Kvinder i den fertile alder / antikonception hos mænd og kvinder
Women of childbearing potential / Contraception in males and females
Kvinder i den fertile alder / kontraception hos kvinder
Women of childbearing potential/ contraception in females
Kvinder i den fertile alder / Kontraception hos mænd og kvinder
Women of childbearing potential / Contraception in males and females
Kvinder i den fertile alder / Kontraception hos mænd og kvinder
Women of childbearing potential/Contraception in males and females
Kvinder i den fertile alder / kontraception til mænd og kvinder
Women of childbearing potential / contraception in males and females
Kvinder i den fertile alder / Prævention til mænd og kvinder
Women of childbearing potential / Contraception in males and females
Kvinder i den fertile alder anbefales kraftigt at anvende passende prævention for at forebygge graviditet og fortsætte med at anvende prævention i mindst fem måneder efter den sidste Humira- behandling.
Women of childbearing potential are strongly recommended to use adequate contraception to prevent pregnancy and continue its use for at least five months after the last Humira treatment.
Kvinder i den fertile alder anbefales kraftigt at anvende sikker kontraception for at undgå graviditet under behandlingen og i mindst 18 uger efter den sidste behandling med Entyvio.
Women of childbearing potential are strongly recommended to use adequate contraception to prevent pregnancy and to continue its use for at least 18 weeks after the last treatment with Entyvio.
Kvinder i den fertile alder bør altid anvende effektiv antikonceptionsmetode under behandlingen.
Women of child-bearing potential must always use effective contraception during treatment.
Kvinder i den fertile alder bør anvende effektiv antikonception under behandling med belatacept og op til 8 uger efter sidste behandlingsdosis, da den potentielle risiko for den embryonale/føtale udvikling er ukendt.
Women of childbearing potential should use effective contraception during treatment with belatacept and up to 8 weeks after the last dose of treatment since the potential risk to embryonic/foetal development is unknown.
Kvinder i den fertile alder bør anvende effektiv prævention, hvis de behandles med FORSTEO.
Women of childbearing potential should use effective methods of contraception during use of FORSTEO.
Kvinder i den fertile alder bør anvende prævention.
Women of child-bearing potential should take appropriate contraceptive measures.
Kvinder i den fertile alder bør anvende sikker kontraception under behandlingen .
Women of child-bearing potential should take appropriate contraceptive measures.
Kvinder i den fertile alder bør benytte passende antikonception.
Women of child-bearing potential have to take appropriate contraceptive measures.
Kvinder i den fertile alder bør derfor bruge effektiv antikonception under et behandlingsforløb med LEMTRADA og i 4 måneder efter behandlingsforløbet.
Therefore, women of child bearing potential should use effective contraceptive measures when receiving a course of treatment with LEMTRADA and for 4 months following that course of treatment.
Kvinder i den fertile alder bør have rådgivning af en specialist med hensyn til mulige virkninger af Zonegran på fostret, og risikoen bør diskuteres med patienten i relation til fordelene, inden behandlingen påbegyndes.
Women of childbearing potential should be given specialist advice regarding possible effects of Zonegran on the foetus and the risk should be discussed with the patient in relation to the benefits before starting treatment.
Kvinder i den fertile alder bør have rådgivning af en specialist med hensyn til mulige virkninger af zonisamid på fostret, og risikoen bør diskuteres med patienten i relation til fordelene, inden behandlingen påbegyndes.
Women of childbearing potential should be given specialist advice regarding possible effects of zonisamide on the foetus and the risk should be discussed with the patient in relation to the benefits before starting treatment.
Kvinder i den fertile alder bør ikke blive gravide, mens de er i behandling med Lynparza og må ikke være gravide, når behandlingen indledes.
Women of childbearing potential should not become pregnant while on Lynparza and not be pregnant at the beginning of treatment.
Kvinder i den fertile alder bør testes for graviditet før behandlingsstart og bør under behandlingen anvende et præventionsmiddel.
Women of childbearing age should be tested for pregnancy before beginning therapy, and during therapy utilise some form of pregnancy contraceptive.
Kvinder i den fertile alder frarådes at blive gravide mens de er i behandling med dette lægemiddel.
Women of childbearing potential should be advised to avoid becoming pregnant while receiving treatment with this medicinal product.
Kvinder i den fertile alder må ikke være gravide eller blive gravide, mens de er i behandling med Akynzeo.
Women of childbearing potential should not be pregnant or become pregnant while on treatment with Akynzeo.
Kvinder i den fertile alder og deres partnere bør tilrådes at undgå graviditet.
Women of childbearing potential and their partners should be advised to avoid pregnancies.
Kvinder i den fertile alder og graviditet
Women of child bearing potential and Pregnancy
Kvinder i den fertile alder og mænd skal anvende sikker kontraception under behandlingen og i 3 måneder efter behandlingen.
Women of childbearing potential and men must use effective contraception during and up to 3 months after treatment.
Kvinder i den fertile alder og prævention hos mænd og kvinder
Women of childbearing potential and contraception in males and females
Kvinder i den fertile alder skal anbefales at anvende sikker kontraception for at undgå graviditet under behandling med temozolomid (TMZ).
Women of childbearing potential should be advised to use effective contraception to avoid pregnancy while they are receiving TMZ.
Kvinder i den fertile alder skal anbefales at anvende sikker kontraception for at undgå graviditet under behandling med temozolomide (TMZ).
Women of child bearing should be advised to use effective contraception to avoid pregnancy while they are receiving TMZ.
Kvinder i den fertile alder skal anbefales at anvende sikker kontraception for at undgå graviditet under behandling med temozolomide (TMZ).
Women of childbearing potential should be advised to use effective contraception to avoid pregnancy while they are receiving TMZ.
Kvinder i den fertile alder skal anbefales at anvende sikker kontraception under behandlingen.
Women of childbearing potential must be advised to use effective contraception during treatment.
Kvinder i den fertile alder skal anvende effektiv antikonception under behandling og i 1 måned efter at have fået den sidste dosis af Lynparza.
Women of childbearing potential must use effective contraception during therapy and for 1 month after receiving the last dose of Lynparza.
Kvinder i den fertile alder skal anvende effektiv kontraception under behandlingen.
Women of childbearing potential have to use effective contraception during treatment.
Kvinder i den fertile alder skal anvende effektive kontraception under behandling med pemetrexed.
Women of childbearing potential must use effective contraception during treatment with pemetrexed.
Kvinder i den fertile alder skal anvende passende kontraception under behandling med zonisamid og i en måned efter seponering. (se pkt.
Women of child-bearing potential must use adequate contraception during treatment with zonisamide and for one month after discontinuation (see section 4.6).
Kvinder i den fertile alder skal anvende sikker kontraception (se pkt.
Effective contraceptive measures must be taken by women of child-bearing potential (see section 4.6).
Kvinder i den fertile alder skal anvende sikker kontraception for at undgå at blive gravide, mens de er i behandling med Dacogen.
Women of childbearing potential must use effective contraceptive measures and avoid becoming pregnant while being treated with Dacogen.
Kvinder i den fertile alder skal anvende sikker kontraception for at undgå graviditet og fortsæ tte med anvendelsen heraf i mindst 6 måneder efter den sidste behandling med Flixabi.
Women of childbearing potential must use adequate contraception to prevent pregnancy and continue its use for at least 6 months after the last Flixabi treatment.
Kvinder i den fertile alder skal anvende sikker kontraception for at undgå graviditet og fortsætte med anvendelsen heraf i mindst 6 måneder efter den sidste behandling med Inflectra.
Women of childbearing potential must use adequate contraception to prevent pregnancy and continue its use for at least 6 months after the last Inflectra treatment.
Kvinder i den fertile alder skal anvende sikker kontraception for at undgå graviditet og fortsætte med anvendelsen heraf i mindst 6 måneder efter den sidste behandling med Remsima.
Women of childbearing potential must use adequate contraception to prevent pregnancy and continue its use for at least 6 months after the last Remsima treatment.
Kvinder i den fertile alder skal anvende sikker kontraception og undgå at blive gravide under behandlingen med Tyverb.
Women of childbearing potential should be advised to use adequate contraception and avoid becoming pregnant while receiving treatment with Tyverb.
Kvinder i den fertile alder skal anvende sikker kontraception og undgå at blive gravide, mens de behandles med asparaginase-indeholdende kemoterapi.
Women of childbearing potential have to use effective contraception and avoid becoming pregnant while being treated with asparaginase-containing chemotherapy.